Organon enters partnerships with Danish upstart on non-hormonal contraception

The deal entails USD 360m in milestone payments in addition to USD 10m in an upfront payment to the Danish developer Cirqle Biomedical.

Photo: Cirqle Biomedical

US-based firm Organon and Danish upstart Cirqle Biomedical, which is focused on women’s health, have inked a partnership and exclusive licensing agreement for a new, non-hormonal contraceptive candidate, the two firms announce in a joint press release.

Cirqle Biomedical is trying to create a non-hormonal contraceptive for women, and the idea behind the project is ”to create a temporary barrier to sperm transport by topically reinforcing the existing cervical mucus barrier,” Cirqle writes, noting that preclinical research seems to support the method.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs